Metabolic Associated Fatty Liver Disease Metabolic diseases Metabolic Associated Fatty Liver Disease Nonalcoholic fatty liver disease Diet Lifestyle Smartphone
Conditions
Interventions
Periodic diet and physical activity recommendation messages/clips and reminder for weight check every 3-7 days via Line official account.,No message or clip broadcasted to this group, only appointment
Experimental Other,Sham Comparator Other
Active Line official account,Non active Line official account
Sponsors
Faculty of Medicine, Prince of Songkla University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Hepatic steatosis diagnosed by imaging techniques or histology within 1 year before screening AND met the definition of MAFLD according to international consensus 2020, 2. Patients are smartphone users with LINE application installed in their smartphones, and use LINE application regularly in daily life, 3. In patients with diabetes mellitus type 2, and/or dyslipidemia, the dosage of medications to treat diabetes and dyslipidemia is stable for at least 3 months
Exclusion criteria
Exclusion criteria: 1. Ongoing treatment with Thiazolidinedione and GLP1 group in type 2 diabetic patients, tamoxifen in breast cancer patients., 2. Coexisted with any active malignancies (with or without treatment), 3. Previous treatment of any malignancies within 6 months., 4. Significant of alcohol consumption (greater than or equal to 21 standard drinks per week in male and greater than or equal to 14 standard drink in female), 5. Concomitant infection or liver disease, which has exact treatment, such as chronic hepatitis B, chronic hepatitis C, autoimmune hepatitis, Wilson(s) disease, 6. Cirrhosis evidence from imaging techniques or histology or LSM more than 17 kPa, 7. Unstable cardiovascular/ cerebrovascular/ pulmonary conditions e.g. recent myocardial infarction or COPD exacerbation within 1 year, 8. Patients unwilling to participate in the study, 9. Pregnancy, 10. Conditions which make unreliable VCTE result
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hepatic steatosis At week 24 Controlled attenuation parameter by Fibroscan | — |
Secondary
| Measure | Time frame |
|---|---|
| Body mass index At week 24 kg/m2,Metabolic parameters At week 24 Blood tests, Bioimpedance Analysis | — |
Countries
Thailand
Contacts
Public ContactPimsiri Sripongpun
Prince of Songkla University
Outcome results
None listed